Jump to ContentJump to Main Navigation

Online

149,00 € / $224.00*

* Prices subject to change. Shipping costs will be added if applicable.
Publication Date:
September 2010
ISSN:
2191-0251
DOI:
10.1515/jpem.2010.126

See all formats and pricing

Online
Individual Subscription Online only
Euro [D] 149.00
RRP for USA, Canada, Mexico
US$ 224.00 *
Print
Individual Subscription Online only
Euro [D] 873.00
RRP for USA, Canada, Mexico
US$ 1310.00 *
Print + Online
Individual Subscription Online only
Euro [D] 1048.00
RRP for USA, Canada, Mexico
US$ 1572.00 *
*Prices subject to change. Shipping costs will be added if applicable.

Editor-in-Chief: Zadik, Zvi

Editorial Board Member: Cassorla, Fernando / Cutfield, Wayne / de Muinck Keizer-Schrama, Sabine M.P.F. / Fideleff, Hugo L. / LaFranch, Stephen H. / Lanes M. D., Roberto / Levitsky, Lynne / Lippe, Barbara / Pfäffle, Roland / Root, Allen W. / Rosenfeld, Ron G. / Werther, George / Kiess, Wieland

12 Issues per year

IMPACT FACTOR 2011: 0.875
5-year IMPACT FACTOR: 1.026

VolumeIssuePage

Issues

Antihyperlipidemic Agents Cause a Decrease in von Willebrand Factor Levels in Pediatric Patients with Familial Hyperlipidemia

S. Songül Yalçin1 / Bülent Güneş1 / Şule Ünal1 / Fatma Gümrük1 / Turgay Coşkun1

1Hacettepe University Faculty of Medicine Department of Pediatrics, 06100, Ankara, Turkey

c1Corresponding author: Prof. Dr. Turgay Coşkun,

c2Corresponding author:

Citation Information: Journal of Pediatric Endocrinology and Metabolism. Volume 23, Issue 8, Pages 765–771, ISSN (Online) 2191-0251, ISSN (Print) 0334-018X, DOI: 10.1515/jpem.2010.126, September 2010

Publication History:
Published Online:
2010-09-17

ABSTRACT

Familial hyperlipidemia is a group of genetic disorders with a predisposition to atherosclerosis. Hyperlipidemia causes increased atherosclerotic events through increased endothelial damage. In this report we aimed to measure the plasma fibrinogen and von Willebrand factor antigen (VWf:Ag) levels in pediatric patients with familial hyperlipidemias and to investigate the effects of serum lipid levels and antihyperlipidemic agents on these parameters. Of the 41 patients analyzed, vWf:Ag level was significantly lower in antihyperlipidemic receivers (132±51%, 102±19%; p=0.010). This finding may indicate that early initiation of antihyperlipidemics in patients with familial hyperlipidemias may decrease the risk of future atherosclerotic events through not only decreasing the serum lipid levels, but also decreasing plasma vWf:Ag levels.

KEY WORDS: familial hyperlipidemia; fibrinogen; von Willebrand factor; treatment

Comments (0)

Please log in or register to comment.